Pharma Industrial India Newsletter [ 2024-07-11]

Open in new window

Pharmaindustrial Mediakit Articles Interviews Appointments Events Magazines

Featured News

Techinvention Lifecare Joins BVI as Consultant for Veterinary Vaccine Manufacturing Facility

Techinvention Lifecare Pvt. Ltd. has announced its appointment as a consultant by Botswana Vaccine Institute (BVI) to monitor the setting up of the new state-of-the-art and cGMP-compliant, vaccine...

Sanofi Starts Shipping US Influenza Vaccines for 2024-25

Sanofi has begun shipped its first influenza (flu) vaccines across the U.S. in preparation for the 2024–25 flu season.

Alembic Pharma Gets USFDA Approval for Bromfenac Ophthalmic Solution

Alembic Pharmaceuticals has secured final approval from the US Food and Drug Administration (USFDA) for its generic Bromfenac Ophthalmic Solution.

Life Molecular Imaging Expands Partnership with Jubilant Radiopharma to Distribute Neurace

Life Molecular Imaging (LMI) has expanded their strategic partnership and licensing agreement with Jubilant Radiopharma to provide and distribute Neuraceq from Jubilant's single photon emission computed...

Lupin Gets Tentative Approval from US FDA for Empagliflozin, Linagliptin and Metformin Hydrochloride

Lupin has secured tentative approval from the United States Food and Drug Administration (US FDA)for its Abbreviated New Drug Application for Empagliflozin, Linagliptin and Metformin Hydrochloride...

Porton J-STAR and ETC to Work on Co-processing Platform Technology Development

Porton J-STAR has announced that Enabling Technologies Consortium (ETC) has awarded a two-year contract to J-STAR to collaborate on ‘Co-processing Platform Technology’.

Ascentage Pharma Olverembatinib Gets Approval from ISAF for Commercialization in Macau China

Ascentage Pharma has announced that its BCR-ABL1 tyrosine kinase inhibitor (TKI), olverembatinib, has been approved by the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative...

Zydus Gets Tentative Approval from USFDA for Azilsartan Medoxomil Tablets

Zydus Lifesciences Ltd. has secured a tentative approval from the United States Food and Drug Administration (USFDA) to market Azilsartan Medoxomil Tablets, 40 mg and 80 mg (USRLD: Edarbi tablets).

ChargePoint Technology UK Enters Indian Market with Localised Team

ChargePoint Technology UK has strengthened its global presence by establishing a localised team in India to support further its existing customers and the growing pharma manufacturing market.

Heron Therapeutics Announces Acceptance of the PAS Application for ZYNRELEF

Heron Therapeutics, Inc. has announced that the FDA acknowledged the receipt of the company's Prior Approval Supplement (PAS) application for ZYNRELEF (bupivacaine and meloxicam) extended-release...

Aurigene and Edity to Partner in Cell Therapy

Aurigene Pharmaceutical Services Ltd. has announced that it will provide discovery services to Edity Therapeutics in cell therapy.

Genezen to Acquire uniQure Commercial Gene Therapy Manufacturing Operations in Lexington

Genezen has inked an agreement to acquire uniQure's commercial gene therapy operations in Lexington, MA, bringing a strategic manufacturing facility and a world-class team of employees to the company.

Anbogen Therapeutics Secures Additional USD 7.3 Million in A+ Round Financing

Anbogen Therapeutics, Inc. has received USD 7.3 million oversubscribed A+ round financing, which is a direct continuation of the USD 12.5 Million Series A on February 1, 2024, bringing the total raised...

Alembic Pharma Secures USFDA Tentative Approval for Bosutinib Tablets

Alembic Pharmaceuticals has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Bosutinib Tablets, 100 mg and 500 mg.

TruDiagnostic Introduces Organ-Specific Aging Analysis from SYMPHONYAge Algorithms

TruDiagnostic has developed epigenetic aging analysis of individual organ systems, using validated and system-specific trained clocks.

AbbVie Announces Acquisition of Celsius Therapeutics

AbbVie has acquired Celsius Therapeutics, Inc., a privately held biotechnology company pioneering new therapies for patients with inflammatory disease.

Merck Announces Update on Xevinapant Program in Locally Advanced Head and Neck Cancer

Merck has discontinued the Phase III randomized TrilynX study evaluating xevinapant plus chemoradiotherapy (CRT) in patients with unresected locally advanced squamous cell carcinoma of the head and...

Sanofi and Biovac to Manufacture Inactivated Polio Vaccines in Africa

Sanofi has signed local manufacturing partnership with Biovacto to produce inactivated polio vaccines (IPV) in Africa.

Skyhawk Therapeutics Inaugurates its State-of-the-Art Labs in Switzerland

Skyhawk Therapeutics, Inc. has expanded its facilities with its new state-of-the-art labs in Superlab Suisse, in Basel Switzerland.

SkyCell Receives USD 116 Million in Series D Funding Round

SkyCell has recently secured a USD 116 million in Series D funding round.

Sen-Jam Pharma Completes Enrollment for Phase 2 URIs or COVID

Sen-Jam Pharmaceutical has completed participant enrollment for the clinical trial of its innovative therapeutic, SJP-002C in partnership with Duke University.

Cypris Therapeutics Bags Over USD 500k in Pre-Seed Funding

Cypris Therapeutics has introduced a breakthrough in synthetic chemistry technology which allows development of novel chemistries for treatment of therapeutically resistant diseases, including brain...

Biocon Biologics Gets EMA Approval for Bevacizumab and its New mAbs Facility in India

Biocon Biologics Ltd. has received approval from the European Medicines Agency (EMA) to manufacture biosimilar Bevacizumab at its new, world-class, multi-product monoclonal antibodies (mAbs) drug...

Sun Pharma Signs Non-Exclusive Patent Licensing Deal with Takeda for Vonoprazan

Sun Pharma has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company Ltd. to commercialise Vonoprazan tablets 10 mg, 20 mg in India under the brand name Voltapraz.

Scenic Biotech Enables Identification of Genetic Modifiers Easy with its Cell-Seq Platform

Q: Why are genetic modifiers challenging to identify using population genetics for rare genetic disorders and how does Scenic Biotech’s products exploring...

This message and any attachments are confidential and privileged and intented for the use of the addressee only. If you have received this communication in error, please notify the sender by replay e-mail and delete this message from your system. Please note that Internet e-mail guarantees neither the confidentiality nor the proper receipt of the message sent. The data deriving from our correspondence with you are included in a file of OMNIMEDIA, S.L. which exclusive purpose is to manage the communications of the company; under the understanding that, in maintaining said correspondence, you authorize the treatment of such data for the mentioned purpose. You are entitled to exercise your rights of access, rectification, cancellation and opposition by addressing such written application to address C/ Pollensa, 2, Edif. Artemisa of. 12 de LA ROZAS (28290 - MADRID) enclosing your NIF or identifying document photocopies of.

Unsubscribe